Full Dataset from Phase 2a trial in Parkinson’s Disease suggest patients treated with bezisterim experienced significant improvements in both non-motor symptoms and motor control while placebo-treated patients worsened
Improvements in non-motor symptoms correlated with improvements
in motor symptoms for Parkinson’s Disease patientsFull Dataset from Phase 2a trial in Parkinson’s Disease suggest patients treated with bezisterim experienced significant improvements in both non-motor symptoms and motor control while placebo-treated patients worsened
Improvements in non-motor symptoms correlated with improvements
in motor symptoms for Parkinson’s Disease patients